Targeting the PI3K p110α isoform inhibits medulloblastoma proliferation, chemoresistance, and migration

Clinical Cancer Research

Volumn 14, Issue 21, 2008, Pages 6761-6769

  Guerreiro, Ana S ^a   Fattet, Sarah ^b,c   Fischer, Barbara ^a   Shalaby, Tarek ^a   Jackson, Shaun P ^d   Schoenwaelder, Simone M ^d   Grotzer, Michael A ^a   Delattre, Olivier ^b   Arcaro, Alexandre ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b INSTITUT CURIE   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110ALPHA; PROTEIN P110BETA; PROTEIN P110DELTA; S6 KINASE; SCATTER FACTOR; SOMATOMEDIN C; UNCLASSIFIED DRUG; YM 024; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, HUMAN; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, HUMAN; ISOENZYME;

APOPTOSIS; ARTICLE; BRAIN TISSUE; CANCER CELL CULTURE; CANCER GROWTH; CATALYSIS; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDULLOBLASTOMA; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL MOTION; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOENZYMES; MEDULLOBLASTOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 58149252480     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0385     Document Type: Article

References (40)

1. Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract 2007;4:295-304.
2. Crawford JR, MacDonald TJ, Packer RJ. Medulloblastoma in childhood: new biological advances. Lancet Neurol 2007;6:1073-85.
3. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004;31:666-75.
4. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24:385-428.
5. Gilbertson R. Paediatric embryonic brain tumours. Biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002;38:675-85.
6. Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005;65:9355-62.
7. Gilbertson RJ, Clifford SC, MacMeekin W, et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 1998;58:3932-41.
8. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80.
9. Andrae J, Molander C, Smits A, Funa K, Nister M. Platelet-derived growth factor-B and -C and active α-receptors in medulloblastoma cells. Biochem Biophys Res Commun 2002;296:604-11.
10. Duplan SM, Theoret Y, Kenigsberg RL. Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 2002;8:246-57.
11. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
12. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001;169:107-14.
13. Wang JY, Del Valle L, Gordon J, et al. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 2001;20:3857-68.
14. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-75.
15. Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 2006;12:3019-27.
16. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004;64:5048-50.
17. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 2004;131:217-28.
18. Del Valle L, Enam S, Lassak A, et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin Cancer Res 2002;8:1822-30.
19. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003;63:140-8.
20. Li Y, Guessous F, Johnson EB, et al. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Investig A J Technol Methods Pathol 2008;88:98-111.
21. von Bueren AO, Shalaby T, Rajtarova J, et al. Antiproliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 2007;7:19.
22. Chaussade C, Rewcastle GW, Kendall JD, et al. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J 2007;404:449-58.
23. Condliffe AM, Davidson K, Anderson KE, et al. Sequential activation of class IB, class IA. PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005;106:1432-40.
24. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110β: a newt arget for antithrombotic therapy. Nat Med 2005;11:507-14.
25. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase δ inneutrophil directional movement. J Immunol 2003;170:2647-54.
26. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25:386-401.
27. Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005;58:483-7.
28. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science New York NY 2004;304:554.
29. Arcaro A, Doepfner KT, Boller D, et al. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J 2007;406:57-66.
30. Benzina S, Fischer B, Miternique-Grosse A, et al. Cell death induced in a human glioblastoma cell line by p(65)+Be neutrons combined with cisplatin. Life Sci 2006;79:513-8.
31. Kagawa N, Maruno M, Suzuki T, et al. Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol 2006;23:41-7.
32. Rossi MR, Conroy J, McQuaid D, Nowak NJ, Rutka JT, Cowell JK. Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer 2006;45:290-303.
33. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003;22:3205-12.
34. Yu HG, Ai YW, Yu LL, et al. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 2008;122:433-43.
35. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.
36. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
37. Gupta S, Ramjaun AR, Haiko P, et al. Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 2007;129:957-68.
38. Zhao JJ, Cheng H, Jia S, et al. The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A 2006;103:16296-300.
39. Urbanska K, Trojanek J, Del Valle L, et al. Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3β constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene 2007;26:2308-17.
40. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 2006;25:7381-90.